| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $25,446 | 1 | 100 |
Sells | $0 | 0 | 0 |
| Murphy Polly A. | director | 1 | $25,446 | 0 | $0 | $25,446 |
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of …
Over the last 12 months, insiders at Atea Pharmaceuticals, Inc. have bought $25,446 and sold $0 worth of Atea Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Atea Pharmaceuticals, Inc. have bought $78,395 and sold $675,139 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Murphy Polly A. (director) — $25,446.
The last purchase of 6,100 shares for transaction amount of $25,446 was made by Murphy Polly A. (director) on 2026‑05‑18.
| 2026-05-18 | Murphy Polly A. | director | 6,100 0.0077% | $4.17 | $25,446 | +16.18% | ||
| 2025-05-18 | Murphy Polly A. | director | 6,100 0.0109% | $4.17 | $25,446 | +24.20% | ||
| 2025-01-16 | BERGER FRANKLIN M | director | 10,000 0.0119% | $3.36 | $33,614 | -5.41% | ||
| 2025-01-15 | BERGER FRANKLIN M | director | 15,000 0.0175% | $3.19 | $47,885 | -5.12% | ||
| 2024-12-10 | Sale | BERGER FRANKLIN M | director | 359,606 0.42% | $2.85 | $1.02M | +6.97% | |
| 2024-09-19 | Sale | Sommadossi Jean-Pierre | President, CEO, and Chairman | 1,841 0.0026% | $4.00 | $7,368 | -15.84% | |
| 2024-09-18 | Sale | Sommadossi Jean-Pierre | President, CEO, and Chairman | 22,187 0.031% | $4.03 | $89,469 | -19.30% | |
| 2024-09-17 | Sale | Sommadossi Jean-Pierre | President, CEO, and Chairman | 33,941 0.0475% | $4.05 | $137,319 | -19.90% | |
| 2024-06-20 | Sale | Polsky Bruce | director | 17,544 0.0212% | $3.49 | $61,144 | -5.41% | |
| 2024-06-05 | Sale | Sommadossi Jean-Pierre | President, CEO, and Chairman | 1,006 0.0014% | $4.00 | $4,024 | -17.17% | |
| 2024-02-01 | Sale | Corcoran Andrea | See Remarks | 15,843 0.0211% | $3.84 | $60,915 | -13.98% | |
| 2024-02-01 | Sale | Sommadossi Jean-Pierre | President, CEO, and Chairman | 56,910 0.0758% | $3.85 | $218,819 | -13.98% | |
| 2024-02-01 | Sale | Hammond Janet MJ | Chief Development Officer | 14,029 0.0187% | $3.84 | $53,913 | -13.98% | |
| 2024-02-01 | Sale | Horga Maria Arantxa | Chief Medical Officer | 15,870 0.0211% | $3.84 | $60,963 | -13.98% | |
| 2024-02-01 | Sale | Vavricka John | Chief Commercial Officer | 11,819 0.0157% | $3.84 | $45,420 | -13.98% | |
| 2024-02-01 | Sale | Foster Wayne | EVP, Chief Accounting Officer | 12,477 0.0166% | $3.84 | $47,904 | -13.98% | |
| 2022-11-14 | Sale | BERGER FRANKLIN M | director | 16,166 0.0289% | $5.16 | $83,352 | -31.57% | |
| 2022-11-11 | Sale | BERGER FRANKLIN M | director | 25,500 0.0455% | $5.15 | $131,333 | -32.40% | |
| 2021-12-20 | Murphy Polly A. | director | 12,000 0.0356% | $8.57 | $102,796 | -21.40% | ||
| 2020-11-03 | Hack Andrew A. F. | director | 250,000 2.0771% | $24.00 | $6M | +10.66% |
| Murphy Polly A. | director | 92145 0.1149% | $384,244.65 | 3 | 0 | +1.4% |
| Hack Andrew A. F. | director | 5615659 7.0017% | $23.42M | 1 | 0 | |
| Rock Springs Capital Management LP | 10 percent owner | 1654724 2.0631% | $6.9M | 1 | 0 | |
| BERGER FRANKLIN M | director | 476897 0.5946% | $1.99M | 3 | 3 | <0.0001% |
$31,123,523 | 108 | 6.46% | $387.86M | |
$64,733,831 | 40 | 5.69% | $299.32M | |
$140,595,157 | 34 | 17.93% | $301.23M | |
$2,471,510 | 19 | 17.33% | $334.18M | |
$10,399,379 | 13 | 13.60% | $302.03M |
| Increased Positions | 43 | +31.85% | 7M | +13.49% |
| Decreased Positions | 54 | -40% | 3M | -5.8% |
| New Positions | 13 | New | 682,685 | New |
| Sold Out Positions | 11 | Sold Out | 683,467 | Sold Out |
| Total Postitions | 124 | -8.15% | 57M | +7.69% |
| Blackrock, Inc. | $29,438.00 | 10.85% | 8.46M | -209,307 | -2.42% | 2025-09-30 |
| Bml Capital Management, Llc | $26,009.00 | 9.58% | 7.47M | -135,849 | -1.78% | 2025-09-30 |
| Fmr Llc | $20,263.00 | 7.47% | 5.82M | +103,015 | +1.8% | 2025-09-30 |
| Tang Capital Management Llc | $16,795.00 | 6.19% | 4.83M | -63,000 | -1.29% | 2025-09-30 |
| Vanguard Group Inc | $16,388.00 | 6.04% | 4.71M | -177,946 | -3.64% | 2025-09-30 |
| Bain Capital Life Sciences Investors, Llc | $8,650.00 | 3.19% | 2.49M | 0 | 0% | 2025-09-30 |
| Geode Capital Management, Llc | $6,611.00 | 2.44% | 1.9M | -25,836 | -1.34% | 2025-09-30 |
| State Street Corp | $6,208.00 | 2.29% | 1.78M | +7,575 | +0.43% | 2025-09-30 |
| Dimensional Fund Advisors Lp | $5,362.00 | 1.98% | 1.54M | +129,453 | +9.17% | 2025-09-30 |
| Renaissance Technologies Llc | $4,273.00 | 1.57% | 1.23M | -6,200 | -0.5% | 2025-09-30 |